Rucaparib: Metastatic Castration-Resistant Prostate Cancer

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Ferry, Robert, P.; Walton, Sherri

    Trial Phone: 321.841.1077 ; 321.841.1907

  • IRB No: 16.147.11

    Principal Investigator: Julio J. Hajdenberg, MD

    Sub Investigators: Landau, Daniel MD

    Phase: Drug: Phase II

    Age Group: Adult

    Secondary Protocol No: CO-338-052

    Treatment: Medication

    Applicable Disease Sites: Prostate

    Therapies Involved: Rucaparib tablets

    ClinicalTrials.gov ID: NCT02952534

  • Objective

    The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

  • Key Eligibility

    Male ≥ 18 years of age
    Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
    Surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM)
    Evidence of disease progression after prior therapy for mCRPC
    Molecular evidence of mCRPC associated with HRD